ADVERTISEMENT
ADVERTISEMENT
Stop treating India as backup: Biopharma leaders bet big on clinical trials
Executives from Bayer, Parexel, Takeda, Unilabs, and Nestlé Health Science agreed that global companies must now approach India with deliberate focus and long-term commitment.
-
Malvika Choudhary - Wed, 07, May 2025
- 14:01 EDT
- 229
leaders at the USAIC 19th Annual Biopharma & Healthcare Summit / New India Abroad
Biopharma leaders at the USAIC 19th Annual Biopharma & Healthcare Summit pushed for India as a core destination in global drug development, stating that the country is rapidly shedding its image as a backup market for clinical trials.
“Let’s stop treating India as a backup. It’s time to make it part of the core strategy” said Badhri Srinivasan, executive chairman of Unilabs at the event hosted by USA-India Chamber of Commerce.
Also Read: Experts discuss AI-driven healthcare advances at TiECon 2025
This post is for paying subscribers only
SUBSCRIBE NOW
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login